Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects the FDA label’s suicidality warning for children/adolescents/young adults with close monitoring, including caregiver day-to-day observation and emphasis on early treatment and dose changes.
Category Scores
Accurate Statements
Use APLENZIN (bupropion) in children/adolescents/young adults for major depressive disorder with monitoring for worsening depression and emergence of suicidal ideation/behavior.
Supported by Section 5.1 and Section 17: label describes worsening depression and emergence of suicidal ideation/behavior (suicidality) in patients with MDD and instructs monitoring for clinical worsening and suicidality.
Include caregiver day-to-day observation.
Supported by Section 5.1: “Such monitoring should include daily observation by families and caregivers.”
Especially early in treatment or with dose changes.
Supported by Section 5.1 and Section 17: monitoring should be especially during the initial few months and “at times of dose changes,” and patients/families should be alert especially early during treatment and when the dose is adjusted up or down.
Unsupported Statements
Contradictions
Important Omissions
The label also advises prescribing the smallest quantity of tablets consistent with good patient management to reduce the risk of overdose as part of the caregiver/family monitoring guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim aligns with label-required monitoring and caregiver observation for suicidality risk in the specified age group and includes the key timing triggers (early treatment and dose changes). A relevant label element about limiting quantities to reduce overdose risk was not included, but this does not contradict the claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of the label’s guidance to prescribe the smallest quantity of tablets consistent with good patient management to reduce overdose risk.
Suggested Improvement
Add that prescriptions should be written for the smallest quantity of tablets consistent with good patient management to reduce the risk of overdose, as stated in Section 5.1.